SynthesisAging2023
NCAPG as a novel prognostic biomarker in numerous cancers: a meta-analysis and bioinformatics analysis.
Synthesis in Aging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 4 citations in OpenAlex.
- NCAPG promotes the malignant progression of endometrioid cancer through LEF1/SEMA7A/PI3K-AKT.Journal of Cancer · 2025Article
- Unveiling the Potential Role of Hesperetin and Emodin as a Combination Therapy to Inhibit the Pancreatic Cancer Progression against the C-Met Gene.Protein and peptide letters · 2025Article
- In smokers, the axis NCAPG/hsa-let-7b-5p/TMPO-AS1 promotes lung adenocarcinoma.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIdentification of effective biomarkers for cancer prognosis is a primary research challenge. Recently, several studies have reported the relationship between NCAPG and the occurrence of various tumors. However, none have combined meta-analytical and bioinformatics approaches to systematically assess the role of NCAPG in cancer.
methodsWe searched four databases, namely, PubMed, Web of Science, Embase, and the Cochrane Library, for relevant articles published before April 30, 2022. The overall hazard ratio or odds ratio and 95% confidence intervals were calculated to assess the relationship between NCAPG expression and cancer survival prognosis or clinical characteristics. Furthermore, the aforementioned results were validated using the GEPIA2, Kaplan-Meier plotter, and PrognoScan databases.
resultsThe meta-analysis included eight studies with 1096 samples. The results showed that upregulation of NCAPG was correlated with poorer overall survival (hazard ratio = 2.90, 95% confidence interval = 2.06-4.10,
conclusionDysregulated NCAPG expression is associated with the clinical prognostic and pathological features of various cancers. Therefore, NCAPG can serve as a human cancer therapeutic target and a new potential prognostic biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.